Bristol-Myers Squibb, Pharmacyclics and Janssen have announced a new clinical trial collaboration agreement that will assess a new combination cancer therapy.
The alliance will see the companies working together to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo in combination with Pharmacyclics and Janssen’s Imbruvica.
A phase I/II study will examine the safety and anti-tumour activity of combining Opdivo and Imbruvica as a potential treatment option for patients with non-Hodgkin lymphoma. This includes diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukaemia.
Janssen will conduct the study which will add to the body of clinical evidence supporting the efficacy of both therapies.
Michael Giordano, senior vice-president and head of development for oncology at Bristol-Myers Squibb, said: “We look forward to working with Pharmacyclics and Janssen to evaluate the potential of these two therapies as options for patients with lymphomas.”